Small cell lung cancer has a high malignancy and limited treatment options. Immunotherapy may be a promising approach

Small cell lung cancer (SCLC) is clinically characterized by high malignancy, rapid tumor growth, early widespread metastasis, and frequent mediastinal involvement. Apart from being sensitive to chemotherapy and radiotherapy, there are no other more effective treatment methods. Patients often have a relatively short survival period, making the treatment different from that of other lung cancers. Today, we present a case of a SCLC patient who underwent NKT cell immunotherapy. Currently, the patient has achieved a stable phase of up to 15 months, with no recurrence or metastasis during this period, and is expected to continue to surpass the 2-year survival mark

 

▲Lung CT: Multiple interstitial fibrosis changes in both lungs, with a 3.3*2.8cm mass shadow visible in the right lower lung on 2019-8-21. Combined with PET-CT imaging on 2019-8-26, it is considered to be a metastatic lesion. On 2019-12-18, the mass shadow gradually shrunk until 2021-3-23. Combined with the history of cyberknife treatment, it is considered to be a post-treatment change. On 2021-3-23, a PET-CT was performed, showing a significant decrease in radioactive uptake compared to 2019-12-18, with tumor activity essentially disappearing. Close observation is recommended.

Click on the image

to view